Serine protease molecules and therapies

Patent metadata

Field	Value
Publication number	US-10323239-B2
Application number	US-201815916743-A
Country	US
Kind code	B2
Filing date	Mar 9, 2018
Priority date	Oct 4, 2012
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

First claim

What is claimed is:

1. A recombinant polypeptide comprising a Granzyme B (GrB) coding sequence at least 85% identical to SEQ ID NO: 1 wherein the GrB coding sequence comprises an amino acid substitution or deletion at the position corresponding to Cys 210, wherein the polypeptide is conjugated to or fused with a cell binding moiety.

2. The polypeptide of claim 1 , wherein the polypeptide further comprises an amino acid sequence comprising a Cys, wherein the amino acid sequence is positioned C-terminally relative to the GrB coding sequence.

3. The polypeptide of claim 2 , wherein the polypeptide further comprises the sequence SSCSGSA (SEQ ID NO: 12) positioned C-terminally relative to the GrB coding sequence.

4. The polypeptide of claim 1 , wherein the polypeptide comprises an Ala substitution at the position corresponding to Cys 210.

5. The polypeptide of claim 1 , wherein the polypeptide is conjugated to the cell binding moiety by a thioester linkage.

6. The polypeptide of claim 1 , wherein the polypeptide fused with a cell binding moiety positioned C-terminally relative to the GrB coding sequence.

7. The polypeptide of claim 1 , wherein the cell binding moiety is a VEGF, BLyS, an antibody or a cell-binding portion of any of the foregoing.

8. The polypeptide of claim 7 , wherein the antibody is a monoclonal, chimeric antibody, Fab′, Fab, F(ab′)2, single domain antibody, Fv, or single chain Fv (scFv) antibody.

9. The polypeptide of claim 7 , wherein the antibody is a human antibody, a humanized antibody or a deimmunized antibody.

10. The polypeptide of claim 7 , wherein the antibody is a 15A8, ZME-018, ScFvMEL, cetuximab or trastuzumab antibody.

11. The polypeptide of claim 1 , wherein the cell binding moiety binds to a protein, carbohydrate or lipid expressed on cancer cells.

12. The polypeptide of claim 1 , wherein the cell binding moiety binds to GP240, 5T4, HER1, HER2, CD-33, CD-38, fltI, Flk-1, CEA, FGFR3, IGFBP2 or IGF-1R.

13. The polypeptide of claim 1 , wherein the polypeptide or cell binding moiety is further conjugated to an imaging agent.

14. The polypeptide of claim 1 , wherein the Granzyme B (GrB) coding sequence is at least 90% identical to SEQ ID NO: 1.

15. The polypeptide of claim 14 , wherein the Granzyme B (GrB) coding sequence is at least 95% identical to SEQ ID NO: 1.

16. The polypeptide of claim 15 , wherein the Granzyme B (GrB) coding sequence is identical to SEQ ID NO: 1.

Assignees

• Res Found Dev

Inventors

• Rosenblum Michael G
• Mohamedali Khalid Amanali
• Cheung Lawrence H

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title